TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By Na
Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Krystal Biotech reported preliminary 4Q 2025 VYJUVEK net revenue of $106-107 million and full-year 2025 revenue of $388-389 million. The company outlined an ambitious strategic vision to become a global leader in rare disease with plans to launch at least four marketed medicines by 2030, treating over 10,000 patients. The company maintains a strong balance sheet with $955 million in cash and investments, and expects combined non-GAAP R&D and SG&A expenses of $175-195 million in 2026.

Insights
JPMpC   neutral

Mentioned as launching tokenization initiatives without specific details about success or scale


KRYS   positive

The company demonstrated strong commercial execution with VYJUVEK generating $388-389 million in full-year 2025 revenue, successful European and Japanese launches, a robust clinical pipeline with multiple potential blockbuster launches expected within four years, a solid balance sheet of $955 million, and ambitious growth targets including four marketed medicines by 2030. The expansion of the KB801 registrational study and multiple clinical milestones planned for 2026 further support positive momentum.